DWTX Dogwood Therapeutics, Inc.
Financings ·
Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026.
Dogwood reported a second quarter net loss of $11.5 million, including a $6.7 million non-cash impairment, and $9.6 million in cash that it says funds operations through the Phase 2b readout.
Dogwood reported a first quarter net loss of $5.0 million and cash on hand of $13.2 million, which it says runs into the fourth quarter of 2026.
Dogwood says a $19.9 million debt exchange with Conjoint and a sale of about $4.8 million in common stock lifted its stockholders' equity above the $2.5 million minimum. Nasdaq had set a May 14, 2025 deadline, and the release does not include a Nasdaq decision.
Dogwood will cancel its loans from Conjoint Inc., a subsidiary of its largest shareholder, for 284.2638 shares of Series A-1 preferred stock convertible into 10,000 common shares each.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $21.9 million | $3.5 million |
| Net income (loss) | -$34.3 million | -$12.3 million |
| Cash from operations | -$15.6 million | -$8.8 million |
| Cash and equivalents | $6.5 million | $14.8 million |
Our latest story on this, dated Mar 12, 2025: "Dogwood Therapeutics exchanges $19.5 million Conjoint loan for preferred stock". The story links the filing or release it is based on. Read the story.
Dogwood Therapeutics, Inc. trades under the ticker DWTX on NASDAQ.
Dogwood Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Dogwood Therapeutics, Inc. is 1818844. Its filings are on SEC EDGAR.
33,992,553 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Dogwood Therapeutics, Inc. under United States.
Our directory classifies Dogwood Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Dogwood Therapeutics, Inc. is US92829J2033.
aibio.space lists Dogwood Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Dogwood Therapeutics, Inc. reported a net loss of $34.3 million for the fiscal year ended Dec 31, 2025, and used $15.6 million of cash in operations, per its annual report to the SEC.
$21.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
$9.6 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Dogwood Therapeutics, dated Oct 19, 2026: "Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences". Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026. Source.
Our latest financing story, dated Oct 19, 2026: "Dogwood Therapeutics agrees to sell $5 million of stock to top holder CK Life Sciences". Dogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026. Source.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio